Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 8/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.38 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.37 |
| ▸ | SMO | Q99835 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6448959 | 0.87 | LSS (0.62) | LSSFAAH | |
| SCHEMBL6450233 | 0.84 | LSS (0.58) | LSSKDM4EHDAC3HDAC4HDAC1 | |
| SCHEMBL4806451 | 0.84 | LSS (0.47) | LSSHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL4806454 | 0.84 | LSS (0.47) | LSSHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL6455119 | 0.79 | LSS (0.65) | LSS | |
| SCHEMBL6450962 | 0.79 | LSS (0.60) | LSSFAAHNAMPT | |
| SCHEMBL5638776 | 0.77 | LSS (0.47) | LSSKDM4E | |
| SCHEMBL6446362 | 0.76 | LSS (0.65) | LSS | |
| SCHEMBL6451133 | 0.76 | LSS (0.67) | LSS | |
| SCHEMBL6450225 | 0.76 | LSS (0.62) | LSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6964974-B2 | 2,3-oxidosqualene-lanosterol cyclase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2005-11-15 | — | — | US | disclosed |
| EP-1583965-A1 | METHOD FOR DETERMINING MOLECULAR AFFINITIES FOR HUMAN SERUM ALBUMIN | Pharmacia & Upjohn Company LLC (US) | 2005-10-12 | — | — | EP | disclosed |
| WO-2004063749-A1 | METHOD FOR DETERMINING MOLECULAR AFFINITIES FOR HUMAN SERUM ALBUMIN | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-07-29 | — | — | WO | disclosed |
| EP-1317432-A1 | PIPERIDINE DERIVATIVES FOR USE AS 2,3-OXIDOSQUALENE-LANOSTEROL CYCLASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-11 | — | — | EP | disclosed |
| US-20020068753-A1 | 2,3-oxidosqualene-lanosterol cyclase inhibitors | HOFFMANN-LA ROCHE INC. | 2002-06-06 | — | — | US | disclosed |
| WO-2002020483-A1 | PIPERIDINE DERIVATIVES FOR USE 2,3-OXIDOSQUALENE-LANOSTEROL CYCLASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068753-A1 | 2,3-oxidosqualene-lanosterol cyclase inhibitors | CYP51A1, LSS, CYP46A1 | LSS 2/4885KDM4E 3840/4885EPHX2 2011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.